Novartis, PTC Therapeutics

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE:NVS) for its PTC518 Huntington’s disease program, which includes related molecules.
PTC Therapeutics signs up to $2.9 billion licensing deal with Novartis
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug for a rare neurological disorder, sending its shares up about 18.5% in premarket trading on Monday.
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.
Why Did PTC Therapeutics, Inc. (PTCT) Stock See 55.85% Surge in the Last 90 Days?
PTC Therapeutics, Inc. (PTCT) stock saw a modest uptick, ending the day at $52.07 which represents a slight increase of $8.19 or 18.66% from the prior close of $43.88. The stock opened at $52.08 and touched a low of $49.
Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological disorder called Huntington's disease, sending the U.S.-based biotech's shares up about 14% on Monday.
Novartis wagers billions of dollars on PTC Huntington’s drug
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing Phase II data in amyotrophic lateral sclerosis.
Novartis signs licensing deal worth up to $2.9B with PTC Therapeutics
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
PTC Therapeutics enters global license, collaboration agreement with Novartis
PTC Therapeutics (PTCT) announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals worth up to $2.9 billion for PTC518, its candidate treatment for Huntington's disease, the companies said in separate Monday statements.
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Stocktwits on MSN1d
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows
Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...
PTC Therapeutics price target raised to $71 from $47 at UBS
UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement ...
Business Insider22h
PTC Therapeutics price target raised to $32 from $26 at Citi
Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, ...
FierceBiotech2d
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
PTC Therapeutics to sell Priority Review Voucher for $150M
PTC Therapeutics (PTCT) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150M upon the closing of the transaction. PTC was granted the ...
The Pharma Letter6d
PTC picks up $150 million via voucher sale
PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...
Pharmabiz6d
PTC Therapeutics’ phase 2 CardinALS study of utreloxastat in ALS patients fails to meet primary endpoint
PTC Therapeutics’ phase 2 CardinALS study of utreloxastat in ALS patients fails to meet primary endpoint: Warren, New Jersey Thursday, November 28, 2024, 15:00 Hrs [IST] PTC The ...